Miromatrix Medical Inc., a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products for soft tissue reinforcement and advanced wound care, unveiled its new manufacturing facility about 50 miles from downtown Minneapolis. The facility features an ISO Class 7 cleanroom suite, a state-of-the-art deionized water system, numerous laminar flow hoods, and an autoclave. The cleanroom will be used to run Miromatrix’ perfusion decellularization process which is part of the manufacturing process for the company’s porcine liver-derived mesh products. The facility will also house the company’s testing, release, warehouse, and distribution functions.
The facility has the capability to support the anticipated growth of the business. Its proximity to the Twin Cities allows Miromatrix to tap into the strong medical technology and healthcare industry presence in the area.